Upregulation of Fatty Acid Transporters is Associated With Tumor Progression in Non-Muscle-Invasive Bladder Cancer

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2021 Jul 14

PMID 34257543

Citations 7

Authors

Hoiseon Jeong

Hwa Eun Oh

Hyesun Kim

Ju-Han Lee

Eung Seok Lee

Young-Sik Kim

Jung-Woo Choi

Affiliations

Soon will be listed here.

Abstract

As patients with non-muscle-invasive bladder cancer (NMIBC) show a high degree of heterogeneity in tumor recurrence or progression, many clinicians demand a detailed risk stratification. Although modified fatty acid metabolism in cancer cells is reported to reflect malignant phenotypes such as metastasis, the impact of fatty acid transporters on NMIBC has never been investigated. This study examined the clinicopathologic implications of fatty acid transporters such as fatty acid transport protein 4 (FATP4), cluster of differentiation 36/fatty acid translocase (CD36/FAT), and long chain acyl CoA synthetase 1 (ACSL1) in 286 NMIBC cases. This study revealed that FATP4, CD36, and ACSL1 were overexpressed in 123 (43.0%), 43 (15.0%), and 35 (12.2%) NMIBC cases, respectively. High FATP4 in tumor cells was associated with high grade ( = 0.004) and high stage ( = 0.039). High CD36 was related to high grade ( < 0.001), high stage ( = 0.002), and non-papillary growth type ( = 0.004). High ACSL1 showed an association with high grade ( < 0.001), high stage ( = 0.01), non-papillary growth type ( = 0.002), and metastasis ( = 0.033). High FATP4 was an independent factor predicting short overall survival (OS) (hazard ratio = 3.32; 95% confidence interval, 1.07-10.31; = 0.038). In conclusion, upregulation of FATP4, CD36, and ACSL1 might promote the NMIBC progression and could be exploited in clinical risk stratification and targeted therapy.

Citing Articles

An Insight into Prognostic Impact of TIPE2 & CD36 Immunohistochemical Expression in Urothelial Carcinoma.

Abd El Maged A, Badr N, Mohammed H Iran J Pathol. 2025; 20(1):48-57.

PMID: 40060230 PMC: 11887630. DOI: 10.30699/ijp.2024.2029525.3301.

Dysregulation of genes involved in the long-chain fatty acid transport in pancreatic ductal adenocarcinoma.

Poenaru R, Milanesi E, Niculae A, Dobre A, Vladut C, Ciocirlan M World J Gastrointest Oncol. 2025; 17(1):98409.

PMID: 39817147 PMC: 11664611. DOI: 10.4251/wjgo.v17.i1.98409.

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.

Harsanyi S, Kianickova K, Katrlik J, Danisovic L, Ziaran S J Cancer Res Clin Oncol. 2024; 150(2):96.

PMID: 38372785 PMC: 10876723. DOI: 10.1007/s00432-024-05623-7.

The Illustration of Altered Glucose Dependency in Drug-Resistant Cancer Cells.

Bishayee K, Lee S, Park Y Int J Mol Sci. 2023; 24(18).

PMID: 37762231 PMC: 10530558. DOI: 10.3390/ijms241813928.

Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression.

Shi Z, Han X, Song Z, Dong Y, Pang K, Wang X Biomark Res. 2023; 11(1):47.

PMID: 37138354 PMC: 10155358. DOI: 10.1186/s40364-023-00488-3.

References

Blackburn C, Guan B, Brown J, Cullis C, Condon S, Jenkins T . Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4. Bioorg Med Chem Lett. 2006; 16(13):3504-9. DOI: 10.1016/j.bmcl.2006.03.102. View

Jiang L, Xiao L, Sugiura H, Huang X, Ali A, Kuro-o M . Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition. Oncogene. 2014; 34(30):3908-16. PMC: 4387121. DOI: 10.1038/onc.2014.321. View

Miryaghoubzadeh J, Darabi M, Madaen K, Shaaker M, Mehdizadeh A, Hajihosseini R . Tissue fatty acid composition in human urothelial carcinoma. Br J Biomed Sci. 2013; 70(1):1-5. DOI: 10.1080/09674845.2013.11669921. View

Schneider H, Staudacher S, Poppelreuther M, Stremmel W, Ehehalt R, Fullekrug J . Protein mediated fatty acid uptake: synergy between CD36/FAT-facilitated transport and acyl-CoA synthetase-driven metabolism. Arch Biochem Biophys. 2014; 546:8-18. DOI: 10.1016/j.abb.2014.01.025. View

Watkins P, Maiguel D, Jia Z, Pevsner J . Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome. J Lipid Res. 2007; 48(12):2736-50. DOI: 10.1194/jlr.M700378-JLR200. View

Bonen A, Chabowski A, Luiken J, Glatz J . Is membrane transport of FFA mediated by lipid, protein, or both? Mechanisms and regulation of protein-mediated cellular fatty acid uptake: molecular, biochemical, and physiological evidence. Physiology (Bethesda). 2007; 22:15-29. DOI: 10.1152/physiologyonline.2007.22.1.15. View

Kim Y, Jung J, Jeong H, Lee J, Oh H, Lee E . High Membranous Expression of Fatty Acid Transport Protein 4 Is Associated with Tumorigenesis and Tumor Progression in Clear Cell Renal Cell Carcinoma. Dis Markers. 2019; 2019:5702026. PMC: 6476224. DOI: 10.1155/2019/5702026. View

Sugino T, Baba K, Hoshi N, Aikawa K, Yamaguchi O, Suzuki T . Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor of prognosis of cancer patients. Med Mol Morphol. 2011; 44(3):146-50. DOI: 10.1007/s00795-010-0517-0. View

Knowles M . Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis. 2005; 27(3):361-73. DOI: 10.1093/carcin/bgi310. View

10.

Bensaad K, Favaro E, Lewis C, Peck B, Lord S, Collins J . Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014; 9(1):349-365. DOI: 10.1016/j.celrep.2014.08.056. View

11.

Stahl A, Hirsch D, Gimeno R, Punreddy S, Ge P, Watson N . Identification of the major intestinal fatty acid transport protein. Mol Cell. 1999; 4(3):299-308. DOI: 10.1016/s1097-2765(00)80332-9. View

12.

Kuo C, Ann D . When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance. Cancer Commun (Lond). 2018; 38(1):47. PMC: 6042406. DOI: 10.1186/s40880-018-0317-9. View

13.

Li Z, Kang Y . Lipid Metabolism Fuels Cancer's Spread. Cell Metab. 2017; 25(2):228-230. DOI: 10.1016/j.cmet.2017.01.016. View

14.

Fermor B, Masters J, Wood C, Miller J, APOSTOLOV K, Habib N . Fatty acid composition of normal and malignant cells and cytotoxicity of stearic, oleic and sterculic acids in vitro. Eur J Cancer. 1992; 28A(6-7):1143-7. DOI: 10.1016/0959-8049(92)90475-h. View

15.

Chen W, Wang C, Hung Y, Weng T, Yen M, Lai M . Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer. PLoS One. 2016; 11(5):e0155660. PMC: 4865206. DOI: 10.1371/journal.pone.0155660. View

16.

Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Stephan-Otto Attolini C . Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2016; 541(7635):41-45. DOI: 10.1038/nature20791. View

17.

Yen M, Chou S, Kan J, Kuo P, Hou M, Hsu Y . Solute Carrier Family 27 Member 4 (SLC27A4) Enhances Cell Growth, Migration, and Invasion in Breast Cancer Cells. Int J Mol Sci. 2018; 19(11). PMC: 6274775. DOI: 10.3390/ijms19113434. View

18.

Kazantzis M, Stahl A . Fatty acid transport proteins, implications in physiology and disease. Biochim Biophys Acta. 2011; 1821(5):852-7. PMC: 3274620. DOI: 10.1016/j.bbalip.2011.09.010. View

19.

Baillie A, Coburn C, Abumrad N . Reversible binding of long-chain fatty acids to purified FAT, the adipose CD36 homolog. J Membr Biol. 1996; 153(1):75-81. DOI: 10.1007/s002329900111. View

20.

Humphrey P, Moch H, Cubilla A, Ulbright T, Reuter V . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016; 70(1):106-119. DOI: 10.1016/j.eururo.2016.02.028. View